Adalimumab + Prednisone + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis

Conditions

Uveitis

Trial Timeline

Aug 1, 2010 → Aug 1, 2014

NCT ID

NCT01138657

About Adalimumab + Prednisone + Placebo

Adalimumab + Prednisone + Placebo is a phase 3 stage product being developed by AbbVie for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01138657. Target conditions include Uveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (9) Active (8)

✅Ixekizumab Prefilled SyringeEli LillyApproved

✅AdalimumabAbbVieApproved

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01124838	Phase 3	Completed	Aug 1, 2010	May 1, 2015	Uveitis
NCT01138657	Phase 3	Completed	Aug 1, 2010	Aug 1, 2014	Uveitis

Competing Products

20 competing products in Uveitis

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32